Carmit Nadri-Shay
General Counsel chez ADVAXIS, INC.
Profil
Carmit Nadri-Shay is currently working as Vice President-Regulatory Affairs at Old Ayala, Inc. and Ayala Pharmaceuticals, Inc. He previously worked as Director-Regulatory Affairs at Kamada Ltd.
and Senior Manager-Regulatory Affairs at Protalix Biotherapeutics Ltd.
He holds a doctorate degree from Ben-Gurion University of the Negev.
Postes actifs de Carmit Nadri-Shay
| Sociétés | Poste | Début |
|---|---|---|
| ADVAXIS, INC. | General Counsel | - |
| AYALA PHARMACEUTICALS, INC. | General Counsel | 01/01/2018 |
Anciens postes connus de Carmit Nadri-Shay
| Sociétés | Poste | Fin |
|---|---|---|
Protalix Biotherapeutics Ltd.
 Protalix Biotherapeutics Ltd. BiotechnologyHealth Technology Part of Protalix Biotherapeutics, Inc., Protalix Biotherapeutics Ltd. is an Israeli company that develops a proprietary plant cell culture technology and innovative bioreactor system. The private company is based in Karmiel, Israel. Protalix Biotherapeutics was acquired by Orthodontix, Inc. on January 03, 2007. | General Counsel | - |
| KAMADA LTD. | General Counsel | - |
Formation de Carmit Nadri-Shay
| Ben-Gurion University of the Negev | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KAMADA LTD. | Health Technology |
| AYALA PHARMACEUTICALS, INC. | Commercial Services |
| Entreprise privées | 2 |
|---|---|
Protalix Biotherapeutics Ltd.
Protalix Biotherapeutics Ltd. BiotechnologyHealth Technology Part of Protalix Biotherapeutics, Inc., Protalix Biotherapeutics Ltd. is an Israeli company that develops a proprietary plant cell culture technology and innovative bioreactor system. The private company is based in Karmiel, Israel. Protalix Biotherapeutics was acquired by Orthodontix, Inc. on January 03, 2007. | Health Technology |
Old Ayala, Inc.
 Old Ayala, Inc. Pharmaceuticals: MajorHealth Technology Old Ayala, Inc. operates as a clinical-stage oncology company. It focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel. | Health Technology |
